Decline in Quantitative Serum HBsAg Level during Consolidation Therapy Following HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir

被引：0
|
作者：
Su, Wen-Pang [1 ]
Peng, Cheng-Yuan [1 ]
Lai, Hsueh-Chou [1 ]
Lin, Chia-Hsin [1 ]
Chuang, Po-Heng [1 ]
Chen, Sheng-Hung [1 ]
机构：
[1] China Med Univ Hosp, Taichung, Taiwan
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1875
引用
收藏
页码：1102A / 1103A
页数：2
相关论文
共 50 条
  • [31] DIFFERENT KINETICS OF SERUM HBSAG DECLINE IN HBEAG-POSITIVE VS HBEAG-NEGATIVE PATIENTS DURING 3 YEARS OF TELBIVUDINE TREATMENT IN CHRONIC HEPATITIS B (CHB)
    Wursthorn, Karsten
    Jung, Mechthild
    Manns, Michael P.
    Lopez, Patricia M.
    Wedemeyer, Heiner
    Naoumov, Nikolai V.
    HEPATOLOGY, 2009, 50 (04) : 536A - 536A
  • [32] ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B
    Wong, Darren
    Littlejohn, Margaret
    Edwards, Rosalind
    Jackson, Kathy
    Revill, Peter
    Gaggar, Anuj
    Kitrinos, Kathryn
    Subramanian, Mani
    Marcellin, Patrick
    Buti-Ferret, Maria
    Janssen, Harry
    Gane, Ed
    Locarnini, Stephen
    Thompson, Alexander
    LIVER INTERNATIONAL, 2018, 38 (10) : 1760 - 1769
  • [33] The combination therapy of Peginterferona and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk
    Xiong, Fang
    Bao, Xuli
    Gu, Na
    Guo, Jia
    Wang, Jinhuan
    Ma, Yanpin
    Yu, Lele
    Gao, Yao
    Tan, Bingqin
    Lu, Jun
    INFECTION GENETICS AND EVOLUTION, 2020, 78
  • [34] PEGINTERFERON IS SUPERIOR TO PROLONGED ENTECAVIR THERAPY FOR SEROLOGICAL RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B
    Zoutendijk, Roeland
    Sonneveld, Milan J.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2011, 54 : 1023A - 1023A
  • [35] Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
    Sherman, Morris
    Yurdaydin, Cihan
    Sollano, Jose
    Silva, Marcelo
    Liaw, Yun-Fan
    Cianciara, Janusz
    Boron-Kaczmarska, Anna
    Martin, Paul
    Goodman, Zachary
    Colonno, Richard
    Cross, Anne
    Denisky, Gail
    Kreter, Bruce
    Hindes, Robert
    GASTROENTEROLOGY, 2006, 130 (07) : 2039 - 2049
  • [36] HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions
    Zhang, Yi-Min
    Yang, Yi-Da
    Jia, Hong-Yu
    Zeng, Lin-Yan
    Yu, Wei
    Zhou, Ning
    Li, Lan-Juan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4407 - 4413
  • [37] HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions
    Yi-Min Zhang
    Yi-Da Yang
    Hong-Yu Jia
    Lin-Yan Zeng
    Wei Yu
    Ning Zhou
    Lan-Juan Li
    World Journal of Gastroenterology, 2014, (15) : 4407 - 4413
  • [38] Effect of the precore mutations on the HBeAg loss and viral breakthrough during lamivudine therapy in HBeAg-positive chronic hepatitis B.
    Kim, SS
    Hwang, YJ
    Kwon, KA
    Jung, MG
    Park, DK
    Kwon, OS
    Kwon, SY
    Kim, YS
    Koo, YS
    Kim, YK
    Choi, DJ
    Kim, JH
    HEPATOLOGY, 2003, 38 (04) : 723A - 723A
  • [39] Antiviral effects of entecavir therapy in HBeAg positive chronic hepatitis B patients
    Sun, Haixia
    Yan, Ying
    Mai, Li
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 449 - 449
  • [40] Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply
    Yaghoobi, M.
    Yuan, Y.
    Hunt, R. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (09) : 993 - 993
12345